Abstract
Low-dose aspirin (LDA) has been increasingly used worldwide to prevent atherothrombotic events. At the same time, the adverse events, most frequent of which are gastrointestinal (GI) ulcers and complications have been raising a big concern with its wider use. These adverse events including reflux and dyspeptic symptoms not only jeopardize adherence of LDA, but my cause more serious outcomes. To reduce GI events by informing best evidence for physicians prescribing LDA, guidelines were published some years ago. Since then, more clinical evidence concerning preventive strategies for upper GI events has been accumulated. Notable differences between East and West are also recognized in terms of primary prevention strategy. Among several options to provide cardiovascular protection with LDA while reducing GI risk, PPI co-therapy is considered to be preferred approach for wider populations according to recent cost-effectiveness analyses based on increasing awareness of importance on adherence of LDA together with declining cost of PPI. This review will focus on these new developments on the prevention of upper gastrointestinal ulcer and complications in LDA users.
Keywords: Low-dose aspirin (LDA), dyspepsia, esophagitis, gastrointestinal ulcer, gastrointestinal bleeding, proton pump inhibitor (PPI), misoprostol, Helicobacter pylori.
Current Pharmaceutical Design
Title:Prevention of Upper Gastrointestinal Ulcer and Complications in Low-Dose Aspirin Users
Volume: 21 Issue: 35
Author(s): Kentaro Sugano
Affiliation:
Keywords: Low-dose aspirin (LDA), dyspepsia, esophagitis, gastrointestinal ulcer, gastrointestinal bleeding, proton pump inhibitor (PPI), misoprostol, Helicobacter pylori.
Abstract: Low-dose aspirin (LDA) has been increasingly used worldwide to prevent atherothrombotic events. At the same time, the adverse events, most frequent of which are gastrointestinal (GI) ulcers and complications have been raising a big concern with its wider use. These adverse events including reflux and dyspeptic symptoms not only jeopardize adherence of LDA, but my cause more serious outcomes. To reduce GI events by informing best evidence for physicians prescribing LDA, guidelines were published some years ago. Since then, more clinical evidence concerning preventive strategies for upper GI events has been accumulated. Notable differences between East and West are also recognized in terms of primary prevention strategy. Among several options to provide cardiovascular protection with LDA while reducing GI risk, PPI co-therapy is considered to be preferred approach for wider populations according to recent cost-effectiveness analyses based on increasing awareness of importance on adherence of LDA together with declining cost of PPI. This review will focus on these new developments on the prevention of upper gastrointestinal ulcer and complications in LDA users.
Export Options
About this article
Cite this article as:
Sugano Kentaro, Prevention of Upper Gastrointestinal Ulcer and Complications in Low-Dose Aspirin Users, Current Pharmaceutical Design 2015; 21 (35) . https://dx.doi.org/10.2174/1381612821666150915105834
DOI https://dx.doi.org/10.2174/1381612821666150915105834 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Peroxisome Proliferator-Activated Receptor-γ in Vascular Biology
Cardiovascular & Hematological Disorders-Drug Targets Potential Use of Dendritic Cells for Anti-Atherosclerotic Therapy
Current Pharmaceutical Design Editorial: Statins and Tissue Plasminogen Activator for Stroke: A Beneficial Combination?
Current Vascular Pharmacology The Diagnosis of Drug-Induced Liver Disease
Current Clinical Pharmacology The Role of Asymmetric Dimethylarginine (ADMA) in Endothelial Dysfunction and Cardiovascular Disease
Current Cardiology Reviews The Nature of Immunological Reaction in the Peripheral Airways of Cigarette Smokers
Current Respiratory Medicine Reviews Importance of Receptor-targeted Systems in the Battle Against Atherosclerosis
Current Pharmaceutical Design EDITORIAL (Thematic Issue: Preeclampsia and Modern Approaches to Diagnosis and Therapy)
Current Women`s Health Reviews Varicella-Zoster Virus Infections During Pregnancy: Epidemiology, Clinical Symptoms, Diagnosis, Prevention and Therapy
Current Pediatric Reviews Application of NMR Metabolomics to Search for Human Disease Biomarkers
Combinatorial Chemistry & High Throughput Screening Bioactive Proteins and Peptides from Soybeans
Recent Patents on Food, Nutrition & Agriculture Leptin-Induced Endothelial Dysfunction: A Target for Therapeutic Interventions
Current Pharmaceutical Design Biomarkers in Cardiomyopathies and Prediction of Sudden Cardiac Death
Current Pharmaceutical Biotechnology Chronic Inflammatory Diseases: Progress and Prospect with Herbal Medicine
Current Pharmaceutical Design New Anti-Anginal Drugs: Ranolazine
Cardiovascular & Hematological Agents in Medicinal Chemistry Autoimmune Hepatitis: Pathophysiology, Diagnosis and Pharmacological Therapy
Current Immunology Reviews (Discontinued) Humans Entrain to Sunlight - Impact of Social Jet Lag on Disease and Implications for Critical Illness
Current Pharmaceutical Design Editorial from Guest Editors [Hot Topic: Children with Congenital Heart Disease (Guest Editors: Kris De Boeck and Tony Reybrouck)]
Current Respiratory Medicine Reviews Mycobacterial DNA GyrB Inhibitors: Ligand Based Pharmacophore Modelling and In Vitro Enzyme Inhibition Studies
Current Topics in Medicinal Chemistry Biological Predictors of Aging and Potential of FTIR to Study Age-related Diseases and Aging Metabolic Fingerprint
Current Metabolomics